Simulations Plus Inc (SLP) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Simulations Plus to Participate in Upcoming Healthcare Investor Conferences

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled...

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

Industry partners to provide funding and data to support ACAT™ model improvements Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a...

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare Simulations Plus, Inc...

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare Simulations Plus, Inc...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities